NAD+ Injections Benefits: Evidence & Biomarker Insights

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ (nicotinamide adenine dinucleotide) injections are marketed to boost cellular energy production and support mitochondrial function, with proponents citing potential benefits for fatigue, cognitive clarity, and age-related metabolic decline. While NAD+ plays a critical role in energy metabolism and sirtuins activation, clinical evidence for injectable NAD+ remains limited and often comes from small observational studies rather than large randomized trials.

Understanding whether NAD+ injections align with your health goals requires examining both the biological plausibility and the actual evidence base. PlexusDx emphasizes biomarker-informed health optimization, recognizing that individual metabolic profiles, mitochondrial efficiency markers, and genetic predispositions in energy pathways may influence how someone responds to NAD+ therapy.

How NAD+ Functions in Cellular Energy and Aging

NAD+ is a coenzyme essential for ATP production in mitochondria and serves as a substrate for sirtuins—proteins involved in cellular repair and longevity pathways. Cellular NAD+ levels decline with age, a pattern linked to metabolic slowdown, reduced energy, and impaired DNA repair mechanisms in some research models.

Proponents of NAD+ therapy argue that replenishing this molecule may restore mitochondrial efficiency and activate longevity pathways. However, the bioavailability of injected NAD+ and its ability to cross cell membranes and replenish intracellular pools remains an area of ongoing investigation, with mixed results in human studies.

Clinical Evidence: What Research Actually Shows About NAD+ Injections

Human clinical trials on NAD+ injections are sparse. Most evidence comes from small observational studies, case reports, and animal models. A 2019 review noted that while NAD+ is biochemically important, human efficacy data for injectable formulations remains inconclusive, and methodological limitations affect many published studies.

Emerging research on NAD+ precursors (like NMN and NR) shows more promise in cellular and animal models, but direct comparison to injectable NAD+ is limited. Claims of improved fatigue, cognitive function, or athletic performance are largely anecdotal. Any evaluation should distinguish between theoretical benefit and demonstrated clinical outcome in humans.

Evidence Type	Study Design	Human Efficacy Status	Key Limitation
Animal & Cell Studies	In vitro, rodent models	Theoretical support only	Does not translate directly to humans
NAD+ Precursor Trials (NMN/NR)	Small human RCTs	Preliminary positive signals	Limited sample size and duration
Injectable NAD+ Human Studies	Observational, case reports	Mostly anecdotal	Lacks placebo control and standardized dosing
Mitochondrial Function Markers	Blood & muscle biomarkers	Mixed results in small cohorts	Unclear if NAD+ injections improve tissue levels

Biomarkers and Metabolic Context: Who Might Benefit Most

NAD+ status cannot be reliably measured in routine blood work, making it difficult to identify true NAD+ deficiency or predict who will respond to supplementation. Some clinicians assess mitochondrial markers like lactate, CoQ10, carnitine, or ATP production capacity to contextualize fatigue or metabolic decline.

Individual factors—age, metabolic rate, exercise status, sleep quality, nutrient intake—influence NAD+ availability and mitochondrial efficiency. A comprehensive metabolic assessment should precede NAD+ therapy to rule out treatable causes of fatigue such as thyroid dysfunction, B-vitamin deficiency, or sleep disorders, which respond to targeted interventions with stronger evidence bases.

Safety Considerations and Provider Guidance Before Starting

NAD+ injections are not FDA-approved therapeutics and are typically offered through wellness clinics or compounding pharmacies. Safety data in humans is limited, adverse event monitoring is inconsistent, and interactions with medications (particularly those affecting sirtuin pathways) have not been thoroughly characterized.

Before considering NAD+ injections, consult a qualified healthcare provider to assess your candidacy, rule out underlying metabolic or nutritional deficiencies, establish baseline fatigue measures, and define realistic outcome expectations. Providers should also clarify dosing protocols, frequency, and duration, as standardization across clinics is minimal.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines predispositions in metabolic and cellular energy pathways, including variants in genes affecting mitochondrial function and glucose metabolism. These genetic insights may help provide context for understanding your baseline metabolic efficiency and how your cells handle energy production, potentially informing a conversation with your provider about whether NAD+ therapy aligns with your risk profile.

Genetic variants related to NAD+ metabolism, sirtuins, and mitochondrial efficiency (such as markers in SIRT1, SIRT3, and mitochondrial pathway genes) can reveal predispositions toward accelerated NAD+ decline or reduced mitochondrial resilience. The test does not predict exact NAD+ response but should be interpreted with a qualified healthcare provider to contextualize fatigue, energy concerns, and personalized wellness strategies.

Understanding your genetic predispositions in energy metabolism can support a more informed conversation with your provider about whether NAD+ supplementation is appropriate for you, or whether evidence-based alternatives (targeted B-vitamin repletion, CoQ10, exercise, sleep optimization) may offer clearer benefit given your individual biochemistry and health status.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is NAD+ and why do NAD+ levels decline with age?

NAD+ is a coenzyme critical for energy production in mitochondria and activation of longevity pathways. Cellular NAD+ declines with age due to increased consumption by DNA-repair enzymes and reduced biosynthesis, though the clinical significance of this decline remains debated.

Is there strong clinical evidence that NAD+ injections improve fatigue or cognitive function?

Human clinical trial data for injectable NAD+ is limited and mostly anecdotal. While animal models and NAD+ precursor studies show promise, direct evidence for injectable NAD+ in humans remains inconclusive, making it difficult to predict individual response.

Can a blood test measure my NAD+ level to see if I need supplementation?

Standard blood tests cannot reliably measure intracellular NAD+ status. Some clinics assess mitochondrial function markers indirectly, but true NAD+ deficiency is not routinely diagnosed in clinical practice, making supplementation decisions largely empirical.

What are the known side effects or safety concerns with NAD+ injections?

Safety data in humans is limited. Reported side effects are generally mild (flushing, nausea, headache), but long-term safety and interactions with medications are poorly characterized. NAD+ injections are not FDA-approved, and oversight varies by clinic.

Can the Precision Peptide Genetic Test predict whether NAD+ injections will work for me?

The test reveals genetic predispositions in metabolic and energy pathways, not exact medication response. Genetic markers may help contextualize your baseline mitochondrial efficiency and metabolic resilience, supporting a more informed discussion with your provider about whether NAD+ aligns with your health profile.

NAD+ Injections Benefits: Biomarker Context and Clinical Considerations

NAD+ injections support cellular energy metabolism and have generated interest for age-related decline and fatigue. Clinical evidence remains mixed, and response may vary based on individual metabolic markers and baseline NAD+ status.